XML 59 R45.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

Fair Value of Financial Instruments - Schedule of Quantitative Information of Fair Value Measurements (Details) - Significant Unobservable Inputs (Level 3) $ in Thousands | Jun. 30, 2024 USD ($) | Dec. 31, 2023 USD ($)
--- | --- | ---
Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investments | $ 3,392,509 | $ 3,057,299
Equity and Warrant Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investments | 109,638 | 116,916
Debt Investments and Other Investment Receivables |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investments | 3,394,196 | 3,066,947
Market Comparable Companies | Equity Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investments | 44,149 | 52,094
Market Comparable Companies | Warrants |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investments | 14,837 | 19,014
Market Comparable Companies | Pharmaceuticals | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investments | 1,176,486 | 971,775
Market Comparable Companies | Technology | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investments | 987,037 | 1,181,823
Market Comparable Companies | Sustainable and Renewable Technology | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investments | 1,457 | 1,678
Market Comparable Companies | Medical Devices | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investments | 30,761 |
Market Comparable Companies | Lower Middle Market | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investments | $ 436,935 | $ 322,162
Market Comparable Companies | Minimum | Hypothetical Market Yield | Pharmaceuticals | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.1036 | 0.1091
Market Comparable Companies | Minimum | Hypothetical Market Yield | Technology | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.1037 | 0.1130
Market Comparable Companies | Minimum | Hypothetical Market Yield | Sustainable and Renewable Technology | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.1172 | 0.1075
Market Comparable Companies | Minimum | Hypothetical Market Yield | Medical Devices | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.1260 |
Market Comparable Companies | Minimum | Hypothetical Market Yield | Lower Middle Market | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.1075 | 0.1254
Market Comparable Companies | Minimum | Premium/(Discount) | Pharmaceuticals | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | (0.0200) | (0.0100)
Market Comparable Companies | Minimum | Premium/(Discount) | Technology | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | (0.0100) | (0.0100)
Market Comparable Companies | Minimum | Premium/(Discount) | Sustainable and Renewable Technology | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.0200 | 0.0075
Market Comparable Companies | Minimum | Premium/(Discount) | Medical Devices | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.0050 |
Market Comparable Companies | Minimum | Premium/(Discount) | Lower Middle Market | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.0000 | (0.0075)
Market Comparable Companies | Minimum | EBITDA Multiple | Equity Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input |  | 12.3
Market Comparable Companies | Minimum | EBITDA Multiple | Warrants |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input |  | 12.3
Market Comparable Companies | Minimum | Revenue Multiple | Equity Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.3 | 0.3
Market Comparable Companies | Minimum | Revenue Multiple | Warrants |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.9 | 0.9
Market Comparable Companies | Minimum | Tangible Book Value Multiple | Equity Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 1.5 | 1.8
Market Comparable Companies | Minimum | Discount for Lack of Marketability | Equity Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.1060 | 0.0711
Market Comparable Companies | Minimum | Discount for Lack of Marketability | Warrants |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.1016 | 0.0621
Market Comparable Companies | Maximum | Hypothetical Market Yield | Pharmaceuticals | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.1858 | 0.2143
Market Comparable Companies | Maximum | Hypothetical Market Yield | Technology | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.1845 | 0.2074
Market Comparable Companies | Maximum | Hypothetical Market Yield | Sustainable and Renewable Technology | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.1172 | 0.1075
Market Comparable Companies | Maximum | Hypothetical Market Yield | Medical Devices | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.1260 |
Market Comparable Companies | Maximum | Hypothetical Market Yield | Lower Middle Market | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.1907 | 0.2015
Market Comparable Companies | Maximum | Premium/(Discount) | Pharmaceuticals | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.0425 | 0.0350
Market Comparable Companies | Maximum | Premium/(Discount) | Technology | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.0325 | 0.0500
Market Comparable Companies | Maximum | Premium/(Discount) | Sustainable and Renewable Technology | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.0200 | 0.0075
Market Comparable Companies | Maximum | Premium/(Discount) | Medical Devices | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.0050 |
Market Comparable Companies | Maximum | Premium/(Discount) | Lower Middle Market | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.0300 | 0.0225
Market Comparable Companies | Maximum | EBITDA Multiple | Equity Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input |  | 12.3
Market Comparable Companies | Maximum | EBITDA Multiple | Warrants |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input |  | 12.3
Market Comparable Companies | Maximum | Revenue Multiple | Equity Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 16.2 | 20.1
Market Comparable Companies | Maximum | Revenue Multiple | Warrants |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 11.3 | 10.2
Market Comparable Companies | Maximum | Tangible Book Value Multiple | Equity Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 1.5 | 1.8
Market Comparable Companies | Maximum | Discount for Lack of Marketability | Equity Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.9258 | 0.9272
Market Comparable Companies | Maximum | Discount for Lack of Marketability | Warrants |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.3296 | 0.3312
Market Comparable Companies | Weighted Average | Hypothetical Market Yield | Pharmaceuticals | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.1320 | 0.1346
Market Comparable Companies | Weighted Average | Hypothetical Market Yield | Technology | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.1348 | 0.1503
Market Comparable Companies | Weighted Average | Hypothetical Market Yield | Sustainable and Renewable Technology | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.1172 | 0.1075
Market Comparable Companies | Weighted Average | Hypothetical Market Yield | Medical Devices | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.1260 |
Market Comparable Companies | Weighted Average | Hypothetical Market Yield | Lower Middle Market | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.1400 | 0.1413
Market Comparable Companies | Weighted Average | Premium/(Discount) | Pharmaceuticals | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.0005 | 0.0004
Market Comparable Companies | Weighted Average | Premium/(Discount) | Technology | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.0033 | 0.0047
Market Comparable Companies | Weighted Average | Premium/(Discount) | Sustainable and Renewable Technology | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.0200 | 0.0075
Market Comparable Companies | Weighted Average | Premium/(Discount) | Medical Devices | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.0050 |
Market Comparable Companies | Weighted Average | Premium/(Discount) | Lower Middle Market | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.0090 | 0.0056
Market Comparable Companies | Weighted Average | EBITDA Multiple | Equity Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input |  | 12.3
Market Comparable Companies | Weighted Average | EBITDA Multiple | Warrants |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input |  | 12.3
Market Comparable Companies | Weighted Average | Revenue Multiple | Equity Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 13.2 | 7.2
Market Comparable Companies | Weighted Average | Revenue Multiple | Warrants |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 4.5 | 4.2
Market Comparable Companies | Weighted Average | Tangible Book Value Multiple | Equity Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 1.5 | 1.8
Market Comparable Companies | Weighted Average | Discount for Lack of Marketability | Equity Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.3454 | 0.3157
Market Comparable Companies | Weighted Average | Discount for Lack of Marketability | Warrants |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.2455 | 0.2170
Liquidation | Pharmaceuticals | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investments |  | $ 8,455
Liquidation | Technology | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investments | $ 62,155 | 0
Liquidation | Other Investment Receivable | Other Investment Receivables |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investments | $ 1,687 | $ 9,648
Liquidation | Minimum | Probability weighting of alternative outcomes | Pharmaceuticals | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input |  | 0.1000
Liquidation | Minimum | Probability weighting of alternative outcomes | Technology | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.2000 | 1.0000
Liquidation | Minimum | Probability weighting of alternative outcomes | Other Investment Receivable | Other Investment Receivables |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.1000 | 0.1000
Liquidation | Maximum | Probability weighting of alternative outcomes | Pharmaceuticals | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input |  | 0.5000
Liquidation | Maximum | Probability weighting of alternative outcomes | Technology | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 1.0000 | 1.0000
Liquidation | Maximum | Probability weighting of alternative outcomes | Other Investment Receivable | Other Investment Receivables |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.5000 | 0.5000
Liquidation | Weighted Average | Probability weighting of alternative outcomes | Pharmaceuticals | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input |  | 0.4183
Liquidation | Weighted Average | Probability weighting of alternative outcomes | Technology | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.6667 | 1.0000
Liquidation | Weighted Average | Probability weighting of alternative outcomes | Other Investment Receivable | Other Investment Receivables |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.4020 | 0.4183
Convertible Note Analysis | Technology | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investments | $ 24,820 | $ 23,244
Convertible Note Analysis | Minimum | Probability weighting of alternative outcomes | Technology | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.0100 | 0.0100
Convertible Note Analysis | Maximum | Probability weighting of alternative outcomes | Technology | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.7000 | 0.5000
Convertible Note Analysis | Weighted Average | Probability weighting of alternative outcomes | Technology | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.5012 | 0.3932
Market Adjusted OPM Backsolve | Equity Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investments | $ 10,845 | $ 11,096
Market Adjusted OPM Backsolve | Warrants |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investments | $ 2,831 | $ 3,074
Market Adjusted OPM Backsolve | Minimum | Market Equity Adjustment | Equity Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | (0.9062) | (0.8614)
Market Adjusted OPM Backsolve | Minimum | Market Equity Adjustment | Warrants |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | (0.4475) | (0.7067)
Market Adjusted OPM Backsolve | Maximum | Market Equity Adjustment | Equity Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.0458 | 0.3269
Market Adjusted OPM Backsolve | Maximum | Market Equity Adjustment | Warrants |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.4634 | 0.3486
Market Adjusted OPM Backsolve | Weighted Average | Market Equity Adjustment | Equity Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | (0.0931) | 0.0747
Market Adjusted OPM Backsolve | Weighted Average | Market Equity Adjustment | Warrants |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | (0.0296) | 0.1317
Discounted Cash Flow | Equity Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investments | $ 32,417 | $ 28,713
Discounted Cash Flow | Minimum | Discount Rate | Equity Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.1293 | 0.1988
Discounted Cash Flow | Maximum | Discount Rate | Equity Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.3353 | 0.3197
Discounted Cash Flow | Weighted Average | Discount Rate | Equity Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.3077 | 0.3051
Other | Equity Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investments | $ 4,559 | $ 2,925
Other | Warrants |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investments |  | 0
Debt Investments originated within 6 months | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investments | 554,672 | 431,512
Imminent Payoffs | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investments | 46,525 | 54,430
Debt Investments Maturing in Less than One Year | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investments | $ 71,661 | $ 62,220

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Value of input used to measure investment owned by investment company. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_InvestmentCompanyInvestmentOwnedFairValueMeasurementInput
Namespace Prefix: | us-gaap_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | instant

X
- Definition Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_InvestmentsFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=htgc_DebtInvestmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=htgc_EquityAndWarrantInvestmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=htgc_DebtInvestmentsAndOtherInvestmentReceivablesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ValuationTechniqueAxis=us-gaap_MarketApproachValuationTechniqueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_EquitySecuritiesByIndustryAxis=htgc_PharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_EquitySecuritiesByIndustryAxis=htgc_TechnologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_EquitySecuritiesByIndustryAxis=htgc_SustainableAndRenewableTechnologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_EquitySecuritiesByIndustryAxis=htgc_MedicalDevicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_EquitySecuritiesByIndustryAxis=htgc_LowerMiddleMarketMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=htgc_MeasurementInputHypotheticalMarketYieldMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=htgc_MeasurementInputPremiumDiscountNettingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputEbitdaMultipleMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRevenueMultipleMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=htgc_MeasurementInputTangibleBookValueMultipleMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_WeightedAverageMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ValuationTechniqueAxis=htgc_ValuationTechniqueLiquidationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_EquitySecuritiesByIndustryAxis=htgc_OtherInvestmentReceivableMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=htgc_OtherInvestmentReceivablesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=htgc_MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ValuationTechniqueAxis=us-gaap_IncomeApproachValuationTechniqueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=htgc_MeasurementInputMarketEquityAdjustmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ValuationTechniqueAxis=htgc_ValuationTechniqueOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ValuationTechniqueAxis=us-gaap_CostApproachValuationTechniqueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ValuationTechniqueAxis=htgc_DebtInvestmentsImminentPayoffsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ValuationTechniqueAxis=htgc_DebtMaturingWithinOneYearMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |